Clinical Trial: A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk

U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT06930573) titled 'A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk' on April 09.

Brief Summary: This study is a single-arm, open-label study. To assess the efficacy and safety of AK112 therapy in patients with resectable hepatocellular carcinoma at high risk of recurrence. The primary endpoint is the 12-month RFS rate of resectable hepatocellular carcinoma.

Study Start Date: Dec. 04, 2024

Study Type: INTERVENTIONAL

Condition: HCC

Intervention: DRUG: AK112

After enrollment, patients receive AK112 at 20 mg/kg, administered via intravenous infusion on day 1 of each cycle, every...